Information Provided By:
Fly News Breaks for April 7, 2017
ILMN
Apr 7, 2017 | 07:39 EDT
BofA/Merrill analyst Derik De Bruin said he came away incrementally more positive Illumina's dominance and on the R&D sequencing market following an industry survey on Next-Generation DNA Sequencing demand. He believes Illumina's HiSeq installed base is more stable than appreciated and NovaSeq further expands the market. De Burin raised Illumina's price target to $195 from $175 and reiterated his Buy rating.
News For ILMN From the Last 2 Days
There are no results for your query ILMN
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.